Company profile: Amarin
1.1 - Company Overview
Company description
- Provider of prescription cardiovascular therapy and clinical research, including VASCEPA/VAZKEPA (icosapent ethyl) to reduce cardiovascular risk in patients with elevated triglycerides and established cardiovascular disease, and the REDUCE-IT global outcomes study evaluating VASCEPA in patients with controlled LDL-C and elevated triglycerides to reduce cardiovascular events.
Products and services
- VASCEPA (icosapent ethyl): A regulatory-approved prescription product that reduces cardiovascular event risk in patients with elevated triglyceride levels and established cardiovascular disease or diabetes with additional risk factors
- REDUCE-IT Study: A global clinical outcomes study evaluating the effect of VASCEPA in patients with controlled LDL-C and elevated triglycerides, focusing on reducing cardiovascular events
- VASCEPA/VAZKEPA (icosapent ethyl): A prescription-grade medication engineered to reduce cardiovascular risk in patients with elevated triglycerides and established cardiovascular disease, leveraging the active ingredient icosapent ethyl
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Amarin
X-Ceptor Therapeutics
HQ: United States
Website
- Description: Provider of novel small molecule therapeutics that modulate nuclear receptors, along with a drug discovery platform for the nuclear receptor gene family, developing candidates to treat cardiovascular and metabolic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full X-Ceptor Therapeutics company profile →
HeartWare
HQ: United States
Website
- Description: Provider of small implantable heart pumps and ventricular assist devices for treating advanced heart failure, offering the HeartWare Ventricular Assist System with LVAD/blood pump, patient accessories, and surgical tools. Products include the Medtronic HVAD System for less-invasive thoracotomy, destination therapy and bridge to transplant, plus HVAD Waveforms, controller logfiles, Autologs, and HVAD patient resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HeartWare company profile →
Ablation Frontiers
HQ: United States
Website
- Description: Provider of cardiac ablation devices for treating atrial fibrillation and other cardiac arrhythmias, including a system of catheters and the GENius Radiofrequency (RF) Generator; received CE Mark in 2006 to market in the European Union; based in Carlsbad, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ablation Frontiers company profile →
Silvergate Pharmaceuticals
HQ: United States
Website
- Description: Provider of pediatric medications, developing and commercializing innovative oral solutions that improve dosing accuracy, safety, and availability. Products include Xatmep (methotrexate) for pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis; Qbrelis (lisinopril) for hypertension (adults/pediatric 6+), adjunct heart failure, and acute MI in adults; and EPANED (enalapril) for hypertension (adults/pediatric >1 month), symptomatic heart failure, and asymptomatic left ventricular dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Silvergate Pharmaceuticals company profile →
BMEYE
HQ: The Netherlands
Website
- Description: Provider of non-invasive cardiovascular monitoring technologies, focused on R&D for finger arterial pressure and cardiac output, offering products such as Finapres, a non-invasive continuous finger arterial pressure technology, serving the Netherlands and international markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BMEYE company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Amarin
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Amarin
2.2 - Growth funds investing in similar companies to Amarin
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Amarin
4.2 - Public trading comparable groups for Amarin
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →